May 13, 2015

Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015

Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14 trial in newly diagnosed glioblastoma Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14… Read More
learn more
May 13, 2015

Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015

Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14 trial in newly diagnosed glioblastoma Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14… Read More
learn more
May 11, 2015

FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma

PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review May 11, 2015 10:54… Read More
learn more
May 11, 2015

FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma

PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review May 11, 2015 10:54… Read More
learn more
May 11, 2015

FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma

PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review May 11, 2015 10:54… Read More
learn more
May 11, 2015

NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma

Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer… Read More
learn more
May 11, 2015

NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma

Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer… Read More
learn more
May 11, 2015

NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma

Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer… Read More
learn more
May 5, 2015

Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Address Challenges in the Glioblastoma Community

Tune-In to GBM initiative will culminate in first GBM Hackathon event to find innovative solutions for patients and caregivers Tune-In to GBM initiative will culminate in first GBM Hackathon event to find innovative solutions for patients and caregivers May 05, 2015 08:00 AM Eastern Daylight Time… Read More
learn more
May 5, 2015

Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Address Challenges in the Glioblastoma Community

Tune-In to GBM initiative will culminate in first GBM Hackathon event to find innovative solutions for patients and caregivers Tune-In to GBM initiative will culminate in first GBM Hackathon event to find innovative solutions for patients and caregivers May 05, 2015 08:00 AM Eastern Daylight Time… Read More
learn more